tbuckley/cabot-search huggingface dataset:
The Rue Mosnier With Flags
Authors: M. Therese Southgate
Journal: JAMA (2004)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Reply to Masaki Shiota and Akira Yokomizo's Letter to the Editor re: Robert J. van Soest, Ellen S. de Morrée, Charlotte F. Kweldam, et al. Targeting the Androgen Receptor Confers In Vivo Cross-resistance Between Enzalutamide and Docetaxel, But Not Cabazitaxel, in Castration-resistant Prostate Cancer. Eur Urol 2015;67:981–5
Authors: Robert J van Soest, Ellen S de Morrée, Charlotte F Kweldam, Erik A C Wiemer, Ron H J Mathijssen, Ronald de Wit, Wytske M van Weerden
Journal: European Urology (2015)
I Have Always Been Fascinated . . .
Authors: J J Frey
Journal: JAMA (2000)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Plastic Surgery History
Authors: Karol A. Gutowski
Journal: JAMA (2005)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 3951: Dual phosphoinositide 3-kinase/Mammalian target of rapamycin inhibitors, GSK2126458 and PKI-587, suppress tumor progression and increase radiosensitivity in nasopharyngeal carcinoma
Authors: Wei Wang, Qi Li, Tongxin Liu, Longhua Chen
Journal: Cancer Research (2014)

Abstract Purpose Although combined chemo-radiotherapy has provided considerable improvements for nasopharyngeal carcinoma (NPC), recurrence and metastasis are still frequent. The phosphoinositide 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway plays a critical role in tumor formation and tumor cell survival after radiation-induced DNA damage. In the present study, we evaluated whether inhibition of PI3K/mTOR by two novel dual inhibitors, GSK2126458 and PKI-587, could suppress tumor progression and sensitize NPC cells to radiation. Experimental Design Four NPC cell lines (CNE-1, CNE-2, 5-8F and 6-10B) were used to analyze the effects of GSK216458 and PKI-587 on cell proliferation, migration, invasion, clonogenic survival, amount of residual γ-H2AX foci, cell cycle and apoptosis after radiation. A 5-8F xenograft model was used to evaluate the in vivo effects of the two compounds in combination with ionizing radiation (IR). Results Both GSK216458 and PKI-587 effectively inhibited cell proliferation and motility in NPC cells and suppressed phosphorylation of Akt, mTOR, S6 and 4EBP1 proteins in a dose- and time-dependent manner. Moreover, both compounds sensitized NPC cells to ionizing radiation (IR) by increasing DNA damage, enhancing G2/M cell cycle delay and inducing apoptosis. In vivo, the combination of IR with GSK2126458 or PKI-587 significantly inhibited tumor growth. Tumor regression was correlated with induction of apoptosis and suppression of the phosphorylation of mTOR, Akt, and 4EBP1. Conclusions GSK2126458 and PKI-587 inhibit tumor progression and increase radiosensitivity by inhibiting PI3K/Akt/mTOR signaling in NPC. Combining IR with a dual PI3K/mTOR inhibitor, either GSK2126458 or PKI-587, might be a promising therapeutic strategy for NPC. Citation Format: Wei Wang, Qi Li, Tongxin Liu, Longhua Chen. Dual phosphoinositide 3-kinase/Mammalian target of rapamycin inhibitors, GSK2126458 and PKI-587, suppress tumor progression and increase radiosensitivity in nasopharyngeal carcinoma. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 3951. doi:10.1158/1538-7445.AM2014-3951
Haemostasis and Thrombosis.
Authors: Arthur L. Bloom, Duncan P. Thomas
Journal: Annals of Internal Medicine (1982)

Section 1 : Intrduction Section 2 : Platelets Section 3 : Endothelium and Cell Wal Section 4 : Blood Coagulation Section 5 : Fibrinolysis Section 6 : Inhibitors of Blood Coagulation and Fibrinolysis Section 7 : Abnormalities of Platelets Section 8 : Abnormalities of Coagulation Section 9 : Arterial Disease Section 10 : Venous Thrombosis Section 11 Antithrombotic Therapy
Abstract #LB-269: MAP-tau expression is prognostic but not predictive for taxane response in metastatic breast cancer
Authors: Maria Teresa Baquero, Karen Lostritto, Mark Gustavson, Annette Molinaro, Robert Camp, Kimberly Bassi, Lyndsay Harris, David Rimm
Journal: Cancer Research (2009)

INTRODUCTION: Taxanes are microtubule stabilizing agents and potent cytotoxic molecules recognized as highly effective chemotherapeutic agents. Varying response rates of 40-60%, depending on treatment setting, suggest the need for a clinical diagnostic with predictive value to determine patient sensitivity to taxane therapy. Microtubule associated proteins (MAPs) mediate polymerization and endogenously alter microtubule stabilization/destabilization. Recently, MAP-tau (Tau), a microtubule stabilizing protein, has been investigated as a useful predictive marker for taxane sensitivity. However, studies evaluating the prognostic and predictive value of MAP-tau have presented conflicting results. Here we measure Tau levels in a retrospective cohort and a prospective Taxane clinical trial to determine its prognostic and predictive value. METHODS: Tau protein expression levels were quantitatively assessed using the AQUA technology in two cohorts: a 480-case Yale-based retrospective collection and a 140-case clinical trial (TAX 307, a randomized clinical trial comparing FAC versus TAC treatment as first line chemotherapy for metastatic breast cancer). Tissue microarray and whole section MAP-tau scores were correlated with clinical and pathologic variables. RESULTS: Prognostic evaluation of the Yale cohort using univariate analysis and median score cutpoint indicated a direct correlation between high MAP-tau expression and overall survival (HR = 0.73, 95% confidence interval [CI] = 0.62-0.85; p   Citation Information:  In: Proc Am Assoc Cancer Res; 2009 Apr 18-22; Denver, CO. Philadelphia (PA): AACR; 2009. Abstract nr LB-269.
Thermography to Detect Inflamed Macrophage-Rich Plaques
Authors: Stefan Verheye, Mark M. Kockx, S. Ward Casscells
Journal: Circulation (2003)

Atherosclerotic Plaques by Optical Coherence Tomography" by Tearney et al in Circulation. 1 It strikes us that the authors state that so far, no approach under investigation for plaque characterization has provided direct evidence of macrophage presence; nevertheless, they feel that their technique is capable of visualizing macrophages.However, we feel that the described technique, although having a good resolution, is just another way of obtaining indirect evidence of macrophage presence.Furthermore, the authors state that both thermography and near-infrared spectroscopy, although promising techniques, are not specific for macrophages.We do agree that these physiological techniques, in combination with morphological techniques, would optimize the information about the plaque.However, we would like to point out that recent reports have shown that temperature heterogeneity is determined by plaque composition and more specifically by the presence of macrophages. 2,3 In atherosclerotic rabbits, we were able to show temperature heterogeneity by using intravascular thermography and to correlate this heterogeneity to the presence of an abundance of macrophages; moreover, lipid-lowering diet, resulting in change of plaque composition by disappearance of macrophages, was associated with disappearance of temperature heterogeneity. 3 Recently, Madjid et al 4 have shown that temperatures correlated well with cell density and proximity of macrophages and poorly with smooth muscle cells.Moreover, temperature heterogeneity was diminished by incubating living human carotid plaques with indomethacin ex vivo.Finally, Stefanadis et al 5 found that temperature correlated with C-reactive protein.These findings suggest that macrophages play a crucial role in temperature heterogeneity.Therefore, we feel that intravascular thermography is a valid technique to identify inflamed "macrophage-rich" plaques.
Ocular Disturbances in Diabetes
Authors: A. D. Ruedemann
Journal: Annals of Internal Medicine (1927)

Article1 July 1927Ocular Disturbances in DiabetesA. D. RUEDEMANNA. D. RUEDEMANNSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-1-1-39 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptDefinite changes are found in the eyes of a large number of patients in whom there is an increased blood-sugar content. One of these changes is functional, the rest are pathological. It is important for the physician to be able to recognize these various changes, not only that he may institute appropriate local treatment but also because of their diagnostic significance.The only functional disturbance associated with hyperglycohemia is that calledglycosuric amblyopia, in which the patient has a definite loss of vision without any evident cause. The visual fields show a central loss of color―of red, of green, or... This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Cleveland Clinic Cleveland, Ohio*Clinical discussion given before the American College of Physicians at the Cleveland Clinic, February 22-25, 1927. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byDevelopment of Controlled Tapered Rolling Method for Manufacturing Tapered Leaf Spring 1 July 1927Volume 1, Issue 1Page: 39-43KeywordsVision ePublished: 1 December 2008 Issue Published: 1 July 1927 PDF downloadLoading ...
Statistics notes: How to randomise
Authors: D. G Altman, J M. Bland
Journal: BMJ (1999)

We have explained why random allocation of treatments is a required feature of controlled trials.1 Here we consider how to generate a random allocation sequence.

Almost always patients enter a trial in sequence over a prolonged period. In the simplest procedure, simple randomisation, we determine each patient's treatment at random independently with no constraints. With equal allocation to two treatment groups this is equivalent to tossing a coin, although in practice coins are rarely used. Instead we use computer generated random numbers. Suitable tables can be found in most statistics textbooks. The table shows an example2: the numbers can be considered as either random digits from 0 to 9 or random integers from 0 to 99.

For equal allocation to two treatments we could take odd and even numbers to indicate treatments A and B respectively. We must then choose an arbitrary place to start and also the direction in which to read the table. The first 10 two digit numbers from a starting place in column 2 are 85 80 62 36 96 56 17 17 23 87, which translate into the sequence A B B B B B …
Abstract 757: ET-D5, first-in-class synthetic selective Protein Phosphatase 1 (PP1) inhibitor with anti-proliferative and anti-vascular activity
Authors: Aurelie Juhem, Delphine Lecercle, Julie Deverchère, Arnaud Gazel, Jean-Claude Florent, Andrei Popov
Journal: Cancer Research (2014)

Abstract In this work we describe ET-D5, a synthetic small molecule serine-threonine protein phosphatase inhibitor with proven in vivo anti-mitotic and anti-vascular properties. The potential anti-cancer properties of serine-threonine protein phosphatase inhibitors have been identified since ancient times (extract from blister beetle mylabris was used in China for cancer treatment as early as in 1264), and several, mostly natural, inhibitors were evaluated in clinical trials. Their development was, however, discontinued due to the toxic effects of these non-selective (PP2A&amp;gt;&amp;gt;PP1) serine-threonine protein phosphatase inhibitors. ET-D5 is a remarkably specific (PP1 versus PP2A) inhibitor with potent anti-mitotic and anti-vascular activities. In vitro, ET-D5 display high efficacy against a wide range of human cancer cells (GI50 values determined were in low nM range for certain cell lines). In addition, ET-D5 disrupts the in vitro preformed capillary tubes (endothelial cells HMEC-1). In vivo experiments confirmed these activities in numerous animal models of human cancer, such as cancer of lung, brain, thyroid, kidney and ovaries. ET-D5 presents interesting pharmacological properties, good toxicology profile and is also active when administered per os. Contrary to many vascular-disrupting agents (VDA) which target tubulin, ET-D5 exerts its activity by selectively inhibiting in vivo protein-phosphatase I (PP1). We confirmed this activity in classical pharmacodynamics experiments, showing PP1 inhibition in xenografted tumors after oral administration of ET-D5. Based on all these results, ET-D5 is scheduled to enter clinical trials in early 2015. Citation Format: Aurelie Juhem, Delphine Lecercle, Julie Deverchère, Arnaud Gazel, Jean-Claude Florent, Andrei Popov. ET-D5, first-in-class synthetic selective Protein Phosphatase 1 (PP1) inhibitor with anti-proliferative and anti-vascular activity. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 757. doi:10.1158/1538-7445.AM2014-757
Abstract P4-07-12: Re-introduction of tumor suppressor miR-34a harbors therapeutic efficacy in triple negative breast cancer
Authors: Brian D Adams, Lajos Pusztai, David L Rimm, Frank J Slack
Journal: Cancer Research (2015)

Abstract Place Holder Abstract Date Expected for Obtaining Final Information for Abstract: 9/14 - 10/14 Triple negative breast cancer accounts for a disproportionate share of the total breast cancer morbidity because of its aggressive behavior, increased incidence in younger women, and lack of effective targeted therapies. MicroRNAs are global regulators of survival and proliferation pathways important in cancer development and tumor maintenance. MicroRNAs function as tumor suppressors and oncogenes, and are highly dysregulated in cancer. Here, we identified miR-34a to be aberrantly lost in triple negative cancer cell lines when compared to both a luminal cancer subtype as well as normal breast cells. Re-introduction of miR-34a in triple negative cancer lines results in inhibition of cell proliferation, reactivation of senescence, and enhances sensitivity to apoptotic-inducing agents. Furthermore, intratumoral delivery of miR-34a into subcutaneously implanted tumors in nude mice delays tumor growth as compared to a scrambled control. In conclusion re-introduction of miR-34a in triple negative breast cancer promotes anti-tumorigenic phenotypes both in vitro and in vivo, and could therefore be used as a therapeutic agent to treat the disease. Citation Format: Brian D Adams, Lajos Pusztai, David L Rimm, Frank J Slack. Re-introduction of tumor suppressor miR-34a harbors therapeutic efficacy in triple negative breast cancer [abstract]. In: Proceedings of the Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2014 Dec 9-13; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2015;75(9 Suppl):Abstract nr P4-07-12.
Analysis of the Trajectory of Osteoarthritis Development in a Mouse Model by Serial Near‐Infrared Fluorescence Imaging of Matrix Metalloproteinase Activities
Authors: Averi A. Leahy, Shadi A. Esfahani, Andrea T. Foote, Carrie K. Hui, Roshni S. Rainbow, Daisy S. Nakamura, Brian H. Tracey, Umar Mahmood, Li Zeng
Journal: Arthritis & Rheumatology (2014)

A major hurdle in osteoarthritis (OA) research is the lack of sensitive detection and monitoring methods. It is hypothesized that proteases, such as matrix metalloproteinases (MMPs), are up-regulated in the early stages of OA development. This study was undertaken to investigate if a near-infrared (NIR) fluorescent probe activated by MMPs could visualize in vivo OA progression beginning in the early stages of the disease. Using an MMP-activatable NIR fluorescent probe (MMPSense 680), we assessed the up-regulation of MMP activity in vitro by incubating human chondrocytes with the proinflammatory cytokine interleukin-1β (IL-1β). MMP activity was then evaluated in vivo serially in a mouse model of chronic, injury-induced OA. To track MMP activity over time, mice were imaged 1-8 weeks after OA-inducing surgery. Imaging results were correlated with histologic findings. In vitro studies confirmed that NIR fluorescence imaging identified enhanced MMP activity in IL-1β-treated human chondrocytes. In vivo imaging showed significantly higher fluorescence intensity in OA knees compared to sham-operated (control) knees of the same mice. Additionally, the total emitted fluorescence intensity steadily increased over the entire course of OA progression that was examined. NIR fluorescence imaging results correlated with histologic findings, which showed an increase in articular cartilage structural damage over time. Imaging of MMP activity in a mouse model of OA provides sensitive and consistent visualization of OA progression, beginning in the early stages of OA. In addition to facilitating the preclinical study of OA modulators, this approach has the potential for future translation to humans.
Imagining futures for the NHS
Authors: R. Smith
Journal: BMJ (1998)

The future is unknowable. “Nothing in the world can one imagine beforehand, not the least thing,” said Rainer Maria Rilke: “Everything is made up of so many unique particulars that cannot be foreseen.” Nobody predicted the explosion of the internet, the faltering of the Far East economies, or the outlawing of the communist party in the former Soviet Union. But many people have predicted the paperless office, the leisure society, and the death of the book—none of which have happened. Yet paradoxically those who look to the future flourish, and the world's biggest and most successful organisations devote resources to imagining futures. The trick is not to predict (although the first box includes some predictions) but rather to gather data on recent trends, talk to lots of smart people to identify drivers of change, and then to relax and imagine scenarios of the future. You then use the scenarios to stretch current thinking and as a “wind tunnel” to test current practices and plans: will they still work in the new world?

The NHS Confederation, Institute of Health Service Management, and International Hospital Federation have been busy imagining future scenarios for the NHS, and the scenarios are due to be acted out at the confederation's conference to celebrate 50 years of the NHS. The team creating the scenarios* identified four drivers of …
THE BIOGRAPHY OF BARON BERZELIUS, M.D., PH.D., LATE PROFESSOR OF CHEMISTRY IN THE UNIVERSITY OF STOCKHOLM; COMMANDER OF THE GRAND CROSS OF THE ORDER OF VASA; KNIGHT OF THE POLAR STAR; GRAND CROSS OF THE NORWEGIAN ORDER OF ST. OLAF; KNIGHT OF THE RUSSIAN ORDER OF ST. STANISLAUS, FIRST CLASS; KNIGHT OF THE PRUSSIAN ORDER OF THE RED EAGLE, SECOND CLASS; OFFICER OF THE FRENCH ORDER OF THE LEGION OF HONOUR, ETC. ETC
Authors: D MUSPRATT
Journal: The Lancet (1851)
Differential Associations of Myopia with Major Age-related Eye Diseases
Authors: Chen-Wei Pan, Carol Y. Cheung, Tin Aung, Chiu-Ming Cheung, Ying-Feng Zheng, Ren-Yi Wu, Paul Mitchell, Raghavan Lavanya, Mani Baskaran, Jie Jin Wang, Tien Yin Wong, Seang-Mei Saw
Journal: Ophthalmology (2012)
Chemistry of Carbon Compounds: A Modern Comprehensive Treatise.
Authors: E. H. Rodd
Journal: JAMA (1952)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal